Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 448 participants.
Also called NCT01224366
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 448 participants
- Sponsor
- Registry
-
NCT01224366
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Belgium, Czechia, Germany, Guatemala, Hong Kong SAR China, Hungary, India, Romania, Slovakia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01224366. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01224366- Content hash
080c491cdd22f91978ba67c37d9459db7cb0624ecb06fb553ab722b459a1c529